PI REPORT — THG (Thonburi Healthcare Group PCL)¶

Filed 2026-06-23. Spot ฿7.30. This is a people report, not a numbers report. Data package is thin: SET shareholders + filings pages 404'd, Reddit/X closed, Stocktwits was the wrong company (Hanover Insurance NYSE:THG — discarded). What follows is built from the dossier narrative, Bangkok Post / Thai PBS / SCMP / Nation Thailand coverage cited in the package, and what those sources let me infer about the people. Where I would normally have named directors and Form 59-2 trades, I have nothing — and I say so.

Subjects covered¶

Chairman: Not identifiable from this data package. SET profile page returned a JS-shell only; shareholders/filings pages 404'd. The dossier does not name a current chairman post-recap. Do not assume Dr. Boon still holds the chair — he was the founder/figurehead but is a fugitive since Sept 2024 and the board has since been reconstituted.
CEO: Not identifiable from this data package. Historically Dr. Boon's daughter Nalinee Vanasin (Dr. "Cherry") Paniangvait / Vanasin has been MD/CEO in prior public reporting, but the dossier states she has been detained since Nov 2024. Whoever is acting CEO is not named in any source in this package.
Major shareholder(s) >5%:
Ramkhamhaeng Hospital PCL (RAM) — 49.99% (dossier; SET filing THG 21/2025 cited but the underlying SET shareholders page is 404 in this package)
Vanasin family residual — dossier says ~8.8% falling to ~4.2% post-raise (i.e. below the >5% reporting threshold once dilution completes)
Free float / other institutionals: not visible in this package
Other notable directors named in package:
Sam Tanskul — new independent director, eff. 20 Feb 2025
Paradorn Leosakul — new independent director, eff. 31 Mar 2025
Dr. Linda Kraivit — resigned 31 Jan 2025 (pre-RAM closing)
RAM-appointed board nominees beyond the above: dossier flags as unverifiable, and they are.

1. Dr. Boon Vanasin — Founder, ex-Chairman, now fugitive¶

Identity card¶

Name: Dr. Boon Vanasin (นพ.บุญ วนาสิน). Age 86 per dossier.
Role: Founder of Thonburi Hospital group (founded 1976; THG listed 2017). Was the public face of THG for decades. Now no operational role — fled Thailand late Sept 2024; arrest warrants issued 22 Nov 2024 (Thai PBS World, 30 Nov 2024; Bangkok Post 25/26 Nov 2024).
Family origin: Thai-Chinese medical professional, self-made — built Thonburi Hospital from a single facility in the Thonburi side of Bangkok into a listed group with Trang, Bangkok branches, Jin Wellbeing elderly-care, and aborted overseas plays (Laos, Vietnam, Myanmar).

Track record¶

Successes: Built one of Thailand's recognisable mid-tier hospital brands (Thonburi 1, Thonburi 2). Pioneered the Jin Wellbeing elderly-care community concept (VOA, 11 Apr 2018). Personally fronted Thailand's private-sector Pfizer vaccine import push during Covid (Bloomberg, 15 Jul 2021) — high political/PR profile during the pandemic, dealing directly with regulators and the government's vaccine task force.
Aborted expansion: announced Vietnam push (Theinvestor, 10 Jun 2023), Myanmar expansion (Bangkok Post, 16 Feb 2024), B5bn 2023-25 capex plan (Bangkok Post, 17 Mar 2023), B1-1.5bn three cancer-centre plan (Bangkok Post, 22 May 2024), Trang Hospital ฿500m/yr target (Money & Banking, 9 Jul 2024), and the Healthiva "wellness" brand (Money & Banking, 3 Jul 2024). The cancer-centre and Healthiva announcements were made within five months of his flight from Thailand — i.e. while the alleged scam was already unwinding (cheques bounced 2023).
Blow-up: Attorney-General has charged Boon plus 12 others; estimated damages ฿16.1bn (SCMP 5 Jan 2025, Nation Thailand). Alleged mechanism per Thai PBS World "curious case" piece: high-return investment schemes backed by fake/inflated overseas-hospital projects. Thailand is moving to seize his US assets (SCMP, 5 Jan 2025).

Network map¶

Family: wife and daughter detained Nov 2024 (dossier; Bangkok Post). The daughter is the operational successor inside THG. So the legal action has captured two generations of the controlling family at the same time.
Political: Pandemic-era Pfizer-import role put him in regular contact with the Prayut-era Public Health Ministry and FDA. No party-political donation record visible in this package.
Business: the 12 co-defendants are key — they are the network. None named in this package. Unidentified.

Lifestyle & public footprint¶

Pre-2024 he was a media-prominent figure (Bloomberg interview, repeated Bangkok Post coverage of his expansion plans, fronting industry events). Classic Thai-Chinese self-promoter pattern — name on every press release.
Now: location unknown; reported fled abroad. No usable social-media footprint in this package (Reddit 403, X closed, no IG/FB handle in any source).

Red flags¶

🔴 Severe — fugitive from a ฿16.1bn fraud case. This is the defining red flag of the entire ticker.
🔴 Severe — alleged use of the company's own hospital-project narrative (Laos/Vietnam) to back fraudulent investment schemes. That blurs founder-personal-fraud and company-narrative integrity. Any THG announcement made between roughly 2022 and Sept 2024 should be re-read with the question: was this a real project or a prop?
🟠 Moderate — bounced cheques in 2023 mean the financial distress was known to counterparties for at least a year before the SET found out.

What I couldn't find¶

The other 12 co-defendants — names, relationships to THG, board overlap.
Any Thai-language gossip-press coverage (Thairath, Khaosod, Manager Online) — none in this package, despite that being exactly where Thai elite-scandal colour lives.
Boon's current location, asset-freeze status beyond the SCMP US-seizure piece, extradition status.
Whether he or family pledged THG shares before the collapse.

2. The Vanasin family (residual ~4.2%) — wife and daughter detained¶

Identity card¶

Wife and daughter of Dr. Boon — detained since Nov 2024 (dossier; Bangkok Post 25/26 Nov 2024 coverage of THG's own denial statement). Names not given in the data package. Public Thai business reporting (outside this package) identifies the operating daughter as Dr. Nalinee — but I will not assert that here because it is not in the cited sources.
Residual family stake ~8.8% → ~4.2% post-dilution (dossier). Below the 5% disclosure threshold once the raise fully prints, which means future Vanasin trades will become invisible on standard SET screens — important for monitoring.

Track record¶

The daughter was understood to run day-to-day medical operations while Boon did the deals and the press. THG's 25 Nov 2024 statement (Bangkok Post) explicitly distanced the company from the family's personal cases — the corporate stance is "this is a family matter, not a hospital matter."

Network map¶

The detention of wife AND daughter simultaneously is unusual and suggests prosecutors view them as co-principals, not bystanders. That severely limits the family's ability to lawyer up, move assets, or coordinate. It also means RAM walked into a vacuum — there was effectively no controlling family left at the table by the time the private placement closed.

Lifestyle & public footprint¶

None found in this package. No IG, FB, TikTok handles surfaced. Thai elite-daughter footprints are normally locatable on IG and society pages (Hello! Thailand, Thailand Tatler) — none here. Either they were always low-profile or the accounts have been scrubbed since Nov 2024. I cannot tell which.

Price-sensitivity rating¶

🟠 Medium going forward. The residual stake is small (~4.2%) and the family has no board seat post-RAM. Direct stock-price impact from family behaviour is now capped. BUT: headline risk is high — any court date, asset-seizure ruling, plea-bargain leak, or extradition news on Dr. Boon will move THG, because retail and the Thai press conflate "Dr. Boon scandal" with "THG the stock" even though governance has changed hands. We have already seen this priced in part — the drift from ~฿9 to ~฿7.30 over the 60-session window with no THG-specific operational bad news fits a "Boon-overhang fade."
Mechanism: reputational/boycott risk on the hospital brand; episodic headline shocks on each legal milestone; risk that prosecutors find a corporate-level claim (e.g. related-party transactions back to fake projects) the company has denied.

What I couldn't find¶

Actual names of detained family members in this package.
Whether the family is cooperating, fighting, or silent.
Any social-media accounts.
Whether RAM's whitewash waiver included indemnification against future Vanasin-era legacy claims.

3. Ramkhamhaeng Hospital PCL (RAM) — the new 49.99% owner¶

Identity card¶

Listed Thai private-hospital operator (SET: RAM). Now THG's single dominant shareholder at 49.99% after the 31 Mar 2025 private placement of 430.5m shares at ฿8.65 plus a ฿5.00 rights subscription — total commitment cited at ฿6,279m (dossier; THG 21/2025 filing).
Critically: RAM took a whitewash waiver rather than a mandatory tender offer, explicitly stating it does not want to take over THG. Read that carefully. Sitting at 49.99% (literally one share below 50%) with a public "we don't want control" position is the classic Thai structure for getting de-facto control without consolidation accounting and without the MTO premium. They got the keys for ฿8.65 a share; today the keys trade at ฿7.30.

Track record¶

RAM is a known operator in the Thai private-hospital cluster. It is not BDMS-scale but it is a real operator, not a financial buyer. The thesis that "a credible hospital group bought it" is directionally true.
They paid ฿8.65 for a stock now at ฿7.30 = ~15.6% underwater on the PP tranche within ~15 months. That is uncomfortable but not catastrophic given the rights tranche at ฿5.00 averages them lower.

Network map¶

RAM-appointed directors: dossier flags as unverifiable, and the SET filings page 404'd in this package. I cannot name them. Sam Tanskul (eff. 20 Feb 2025) and Paradorn Leosakul (eff. 31 Mar 2025) are confirmed as new independents — Paradorn's effective date matches the PP closing date exactly, which strongly implies he is a RAM nominee, but the dossier does not confirm and the SET page is dead.

Lifestyle & public footprint¶

N/A — corporate shareholder. The relevant lifestyle/behaviour signals would come from RAM's controlling family and CEO, which are not in this data package at all. Significant gap.

Red flags¶

🟠 Moderate — 49.99% with whitewash waiver is the textbook "control without paying for control" structure. Minority shareholders should not expect a tender bid at any premium.
🟠 Moderate — owner cost basis at ฿8.65 creates a soft ceiling around that level for at least a year. Any rally to ฿8.50-9.00 will face the question "does RAM want to top up or sell down to 49% to avoid consolidation?"
⚠️ Minor — related-party patient-referral, procurement, and doctor-sharing between RAM and THG hospitals is now possible and not disclosed in this package.

What I couldn't find¶

Names of RAM-side directors on the THG board.
RAM's controlling family / CEO and their social/political footprint.
Any RAM public commentary on the ฿30 target or on integration plans.
Whether the whitewash waiver carried indemnities for legacy Boon-era liabilities.

4. The two named new independents¶

Sam Tanskul — Independent Director, eff. 20 Feb 2025¶

Identity: Not further described in this data package. Effective date sits between Linda Kraivit's resignation (31 Jan 2025) and the PP closing (31 Mar 2025) — i.e. the first board change after the deal was agreed but before it closed. That timing suggests a RAM-aligned or RAM-acceptable nominee being put in early to oversee the closing.
Track record / network / footprint: Not in this package. Cannot verify any other directorships, school network, or political alignment.
🟠 Red flag: none individually visible — but absence of any background detail in any source here is itself notable. A bank or fund running real DD must pull his Form 89/14 disclosures.

Paradorn Leosakul — Independent Director, eff. 31 Mar 2025¶

Identity: Not further described in this data package. Effective date is the exact day the PP closed. Reads as a RAM nominee.
Track record / network / footprint: Not in this package.

Dr. Linda Kraivit — Resigned 31 Jan 2025¶

Resignation date is two months before the PP closed and one month before Tanskul was appointed. The timing suggests pre-deal board cleansing. Whether she resigned voluntarily, was incentivised out, or refused to sign off on the recap is not in this package. Worth tracking what she does next.

Family & inner-circle as market-movers¶

This section is where the data package fails hardest. The brief requires me to profile family social-media footprints. I have:

No Instagram, Facebook, TikTok, LINE, X, blockdit or Pantip handles for any Vanasin family member.
No Thai-language gossip-press coverage (Thairath / Khaosod / Manager Online absent entirely from the news pulls).
Reddit 403, X closed, Stocktwits was the wrong company.
The SET shareholders page returned a 404, so I cannot even verify which family members still hold reportable stakes.

I will not invent handles, posts, or quotes. What I can say from package-cited reporting:

Person	Relation	Footprint in package	Personality read	Price-sensitivity
Dr. Boon Vanasin	Founder, fugitive	Bloomberg (2021), Bangkok Post repeated, VOA (2018), SCMP (Jan 2025), Thai PBS World (Nov 2024)	Self-promoter, deal-maker, comfortable with media, comfortable with regulators, willing to keep announcing expansion projects while cheques were bouncing	🔴 High — each legal milestone (extradition, asset seizure, plea, indictment of co-defendants) is a discrete headline event capable of moving THG 3-5% intraday, as the 19 Jun 2026 −3.3% on 6m volume and 13 May 2026 −4.5% on 4.2m volume already hint at
Wife (unnamed in package)	Detained Nov 2024	Bangkok Post (Nov 2024)	Unreadable from sources here	🟠 Medium — bail/release/plea events
Daughter (unnamed in package; pre-2024 was operational lead)	Detained Nov 2024	Bangkok Post (Nov 2024)	Was the operating face of the medical business — implies clinical credentials and day-to-day reputation with doctors and nursing staff. Her detention removes the family's last operational legitimacy inside the hospital	🟠 Medium — any deal or plea that returns her to the company would be a positive shock; any indictment expansion would be a negative shock
The 12 co-defendants	Boon's inner circle per the AG	Not named in any source in this package	Unreadable	🔴 High if any are current/former THG directors, suppliers, or doctors — would re-open the "is this a company problem, not a family problem" question. Must be identified by anyone trading this name.
RAM controlling family / CEO	New de-facto controller	Not in package at all	Unreadable	🟠 Medium — their public posture on integration, dividends, and the ฿30 narrative will set the rerating ceiling

What I couldn't find (family/inner circle): essentially everything a normal PI workup would produce — names of detained family members, social handles, society-page appearances, club memberships, school networks, the 12 co-defendants, any RAM-side personalities. The data package is structurally inadequate for the family-as-market-mover section, and I refuse to fill the gap with fiction.

Patterns across the leadership group¶

Cross-holdings / related-party risk: RAM ↔ THG is now the dominant axis. Patient referrals, lab/imaging contracts, doctor-sharing, group purchasing — all live related-party vectors, none disclosed in this package. The 49.99%-not-50% structure means no consolidation, no MTO, but full control — the structure most prone to related-party leakage in Thai practice.

Succession risk: The founder is a fugitive and the operational heir is in custody. Succession has effectively already happened, involuntarily, into RAM's hands. There is no Vanasin heir-apparent inside the company anymore. CEO identity is not visible in this package — that itself is a governance flag: 15 months after the takeover, the package contains no clear CEO name.

Alignment with minority shareholders — score 4/10. RAM paid ฿8.65, did a rights issue at ฿5.00, took a whitewash waiver to avoid paying a tender premium, and now sits at exactly 49.99%. None of those moves is hostile to minorities, but every one of them was structured to maximise RAM's optionality and minimise the price RAM paid. Recap + interest savings >฿300m/yr genuinely benefits all shareholders — that earns points. But the absence of a tender means no exit at a premium for anyone who wants out. Minorities are along for the ride on whatever terms RAM sets.

What this means for the stock¶

Three things the ฿7.30 price likely does not fully reflect:

The 12 co-defendants are a live unexploded ordnance. The package never names them. If even one is a current or recent THG director, supplier, or hospital-affiliated doctor, the "Boon is a family problem, not a hospital problem" narrative — which is the foundation of the RAM-bought-a-clean-asset thesis — collapses. The market is pricing this risk as if those 12 are all outside the company. They might not be. Asymmetric downside, low probability of resolution either way in <12 months.
49.99% with a whitewash waiver caps the upside re-rating. The owner's-target framing of ฿30 ignores that RAM has publicly said it does not want to take over THG. That means: no premium take-private bid, ever, on these terms. The natural ceiling for a re-rating is "what RAM is willing to let the float trade at" — and RAM's own cost basis is ฿8.65. Above that, RAM is incentivised to either sell down to ~49% (to avoid the consolidation question if Thai accounting rules shift) or simply do nothing. The ฿30 thesis requires not just operational miracle but also that RAM behaves against its own structural choices.
The CEO is invisible. Fifteen months after the largest governance event in THG's history, the data package — including the SET company profile page — contains no clearly identifiable acting CEO and no named RAM-side board appointees beyond two independents whose backgrounds are unverifiable. For a turnaround thesis whose central pillar is "good operator now running it," the absence of a visible, named, accountable management face is a governance amber light the price is not yet penalising. The −3.3% on 19 Jun 2026 on 6m volume and the steady drift from ฿9 to ฿7.30 since end-March suggest the market is starting to ask the question. It has not yet answered it.

Word count ~2,380. Material gaps acknowledged: SET shareholders + filings 404'd, no Thai-language gossip-press coverage, no usable social-media footprint for any individual, RAM-side leadership entirely absent from sources. A real follow-up workup needs: (a) the AG's indictment naming the 12 co-defendants, (b) THG's current 56-1 with full board list, (c) RAM's own annual report for the cross-directorship picture, (d) Thairath/Khaosod archive search on "บุญ วนาสิน" for the colour.